Implantable therapy systems and methods

Claims

What is claimed is:

1. A system for delivering a biologically active factor to a selected treatment site in a subject, comprising:

i) a single cannula adapted for penetration through tissue into a selected position in proximity with the treatment site, having a bore with a substantially smooth interior surface running axially therethrough through which a vehicle may slidably move, an open, proximal end into which the vehicle may be slidably inserted and a distal end having an opening through which the vehicle may slidably move wherein the external diameter and bore diameter are tapered toward the distal tip;

ii) an obturator disposable within the cannula to prevent tissue material from entering the distal end of the cannula when it is inserted into tissue;

iii) a vehicle which encapsulates the biologically active factor, the vehicle having an outer surface which comprises a biocompatible semipermeable outer membrane through which the biologically active factor may be released into the selected treatment site, and a shape which enables slidable insertion into the proximal end of the cannula, slidable movement along the bore of the cannula, slidable passage through the distal end of the cannula by removal of the cannula from the proximity of the treatment site; and

iv) a pusher disposable within the cannula to engage the outer surface of the vehicle, to slidably move the vehicle through the bore, and to hold the vehicle in place at the selected treatment site when the cannula is removed from the proximity of the treatment site, the pusher being removable after the vehicle is positioned at the treatment site.

2. The system of claim 1, further comprising:

i) a guidance needle having a lumen running axially therethrough and being insertable into proximity with the treatment site;

ii) a guidewire insertable into proximity with the treatment site and able to pass completely through the lumen of the guidance needle;

wherein the cannula is adapted to receive the guidewire and wherein the lumen of the guidance needle has a first open end for receiving the guidewire, and a second open end for passage of the guidewire to the treatment site, the guidance needle being fully removable after insertion of the guidewire to the treatment site without disturbing the proximity of the guidewire to the treatment site, and the guidewire being able to guide the insertion of the cannula to the treatment site.

3. The system of claim 2, further comprising at least one dilator disposable along the guidewire to enlarge a pathway through which the cannula is inserted, the dilator having a dilator bore running axially therethrough and able to pass the guidewire therein.

4. The system of claim 3, wherein the guidance needle has a beveled, curved tip.

5. The system of claim 2, further comprising at least one obturator for insertion within and along the lumen of the guidance needle to prevent backfill of materials into the guidance needle during insertion of the guidance needle, the obturator being fully removable after insertion of the guidance needle into proximity with the treatment site.

6. The system of claim 1, wherein at least a portion of the proximal end of the cannula is transparent to permit monitoring the progress of the vehicle during insertion into the cannula and during passage through the transparent portion of the cannula.

7. The system of claim 1, wherein the distal end of the cannula is rounded to reduce ancillary tissue damage, and wherein the active factor comprises at least one neuroactive factor selected from the group consisting of peptide neurotransmitters, growth factors, trophic factors, catecholamines, opioid peptides and hormones.

8. The system of claim 1, wherein the system is adapted for delivering the vehicle into a human spinal region, and wherein the vehicle releases at least one antinociceptive agent useful in a treatment for pain relief.

9. The system of claim 1, wherein the vehicle encapsulates cells that secrete the biologically active factor.

10. The system of claim 9, wherein the encapsulated cells comprise adrenal medullary chromaffin cells.

11. The system of claim 9, wherein the distal end of the cannula is rounded to reduce ancillary tissue damage, and wherein the active factor comprises a neuroactive factor selected from the group consisting of peptide neurotransmitters, growth factors, trophic factors, catecholamines, opioid peptides and hormones.

12. The system of claim 1, wherein the vehicle further comprises an impermeable protective barrier material which coats a portion of the outer membrane.

13. The system of claim 1, wherein the cannula is constructed from material comprising a low friction polymer.

14. The system of claim 13, wherein the polymer comprises polytetrafluoroethylene.

15. The system of claim 1, wherein the active factor comprises at least one antinociceptive agent useful in a treatment for pain relief.

16. The system of claim 1, wherein the cannula is flexible for the delivery of the vehicle through a curved pathway.

17. A method for delivering a biologically active factor to a selected treatment site in a subject, comprising:

i) surgically opening an insertion site located near the selected treatment site;

ii) inserting a single cannula adapted for penetration through tissue and an obturator disposed therein into the insertion site and placing the distal end of the cannula at a selected position in proximity with the treatment site, the cannula having a bore with a substantially smooth surface running axially therethrough through which a vehicle may slidably move, an open, proximal end into which the vehicle may be slidably inserted and a distal end having an opening through which the vehicle may slidably move wherein the external diameter an bore diameter are tapered toward the distal tip;

iii) removing the obturator from the cannula;

iv) introducing within the bore of the cannula a vehicle which encapsulates the biologically active factor, the vehicle having an outer surface which comprises a biocompatible semipermeable outer membrane through which the biologically active factor may be released into the selected treatment site, and a shape which enables slidable insertion into the proximal end of the cannula, slidable movement along the bore of the cannula, slidable passage through the distal end of the cannula by removal of the cannula from the proximity of the treatment site;

v) delivering the vehicle to the distal end of the cannula with a pusher disposable within the cannula to engage the outer surface of the vehicle, to slidably move the vehicle through the bore, and to hold the vehicle in place at the selected treatment site when the cannula is removed from the proximity of the treatment site;

vi) removing the cannula from the tissue, while leaving the vehicle inserted at the treatment site; and

vii) removing the pusher from the tissue.

18. The method of claim 17, further comprising before a step of inserting the cannula,

i) inserting a guidance needle having a lumen running axially therethrough into proximity with the treatment site;

ii) inserting a guidewire through the lumen of the inserted needle and into proximity with the treatment site, the guidewire able to pass completely through the lumen of the guidance needle; and

iii) removing the guidance needle from the treatment site without disturbing the proximity of the guidewire to the treatment site; wherein the cannula is adapted to receive the guidewire and wherein the lumen of the guidance needle has a first open end for receiving the guidewire, and a second open end for passage of the guidewire to the treatment site, the guidance needle being fully removable after insertion of the guidewire to the treatment site without disturbing the proximity of the guidewire to the treatment site, and the guidewire being able to guide the insertion of the cannula to the treatment site.

19. The method of claim 18, further comprising disposing, after removing the guidance needle, at least one dilator along the guidewire and towards the treatment site to enlarge a pathway through which the cannula is inserted, the dilator having a dilator bore running axially therethrough and able to pass the guidewire therein, the dilator being removed before the cannula is removed.

20. The method of claim 18, further comprising, before a step of inserting the guidewire, disposing at least one obturator in the lumen of the guidance needle, the obturator of the type designed for insertion within and along the lumen of the guidance needle to prevent backfill of materials into the guidance needle during insertion of the guidance needle into proximity with the treatment site, the obturator being removed before the guidewire is inserted.